Lattice Biologics Ltd. Announces Change in Director and Change in Status of Chief Operating Officer

BELGRADE, Mont.--()--Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBLTF) (“Lattice Biologics” or the “Company”) announces a change in its Board of Directors and chief operating officer.

“We appreciate Mario’s time and dedication, and wish him the best in the future”

Board of Director Mario Stifano resigned his position effective December 12, 2017, due to conflicting time priorities. “We appreciate Mario’s time and dedication, and wish him the best in the future,” states Guy Cook, CEO.

Darrell Holmes, chief operating officer, resigned his position on December 1, 2017, to pursue other commercial opportunities. Both Stifano and Holmes are eligible to act as an advisor or consultant to the Company, and the Company may elect to retain their services in the future.

Subscribe to Lattice News Updates
Follow us on Twitter: @LatticeBio

About Lattice Biologics Ltd.:

Lattice Biologics Ltd. is an emerging precision medicine leader in the field of cellular therapies and tissue engineering, with a focus on pain management. As a manufacturer of the highest quality allografts, Lattice is focused on next generation products to improve surgical outcomes.

Lattice Biologics operates headquarters, laboratory and manufacturing facilities in Belgrade, Montana. The Company maintains all necessary licensures to process and sell its tissue engineered products within the U.S. and internationally.

Cautionary Statement on Forward-Looking Information:

Certain information contained in this news release constitutes “forward-looking statements” within the meaning of the ‘safe harbour’ provisions of the United States Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements herein, other than statements of historical fact, are to be considered forward looking. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “planned,” “potential,” “future,” “expected,” “could,” “possible,” “goal,” “intends,” “will” or similar expressions. Forward-looking statements in this news release include, without limitation: information pertaining to the Company’s strategy, plans, or future financial performance, such as statements with respect to future revenues or products, and other statements that express management’s expectations or estimates of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Lattice to be materially different from those expressed or implied by such forward-looking statements. Such risks include but are not limited to: the risk that the Company may not be able to generate sufficient cash to service its indebtedness and uncertainty regarding the ability to consummate the debt restructuring transaction.

Contacts

Lattice Biologics Ltd.
Cheryl Farmer, 480-563-0800
CFO
News@LatticeBiologics.com
www.LatticeBiologics.com

Recent Stories

RSS feed for Lattice Biologics Ltd.

Lattice Biologics Ltd.